EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells

Kenji Morimoto, Tadaaki Yamada, Soichi Hirai, Yuki Katayama, Sarina Fukui, Ryo Sawada, Yusuke Tachibana, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kei Kunimasa und 13 weitere

Cancer Letters · 2024-04 · 587 · 216692

DOI: 10.1016/j.canlet.2024.216692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-04. Verfasst von Kenji Morimoto und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 60…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science, Cancer Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, novel Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitors have been clinically developed to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients. However, achieving complete tumor remission is challenging. Therefore, the optimal combined therapeutic intervention with KRAS G12C inhibitors has a potentially crucial role in the clinical outcomes of patients. We investigated the underlying molecular mechanisms of adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutated NSCLC cells to devise a strategy preventing drug-tolerant cell emergence. We demonstrate that AXL signaling led to the adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutated NSCLC, activation of which is induced by GAS6 production via YAP. AXL inhibition reduced the viability of AXL-overexpressing KRAS G12C-mutated lung cancer cells by enhancing KRAS G12C inhibition-induced apoptosis. In xenograft models of AXL-overexpressing KRAS G12C-mutated lung cancer treated with KRAS G12C inhibitors, initial combination therapy with AXL inhibitor markedly delayed tumor regrowth compared with KRAS G12C inhibitor alone or with the combination after acquired resistance to KRAS G12C inhibitor. These results indicated pivotal roles for the YAP-GAS6-AXL axis and its inhibition in the intrinsic resistance to KRAS G12C inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansProto-Oncogene Proteins p21(ras)Signal TransductionApoptosisPathologic Complete ResponseMutation

Stichwörter der Autor:innen

AXLAdaptive resistanceKRAS G12C

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. Electronic address: tayamada@koto.kpu-m.ac.jp.
  • Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • First Department of Internal Medicine, Asahikawa Medical University Hospital, Hokkaido, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
  • Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Förderung

  • Takeda Science Foundation
  • Japan Society for the Promotion of Science
  • Cancer Research Institute
  • Cancer Research Institute, Kanazawa University
  • Princess Takamatsu Cancer Research Fund
  • Kanazawa University

Zitieren

APA

Morimoto, K., Yamada, T., Hirai, S., Katayama, Y., Fukui, S., Sawada, R., Tachibana, Y., Matsui, Y., Nakamura, R., Ishida, M., Kawachi, H., Kunimasa, K., Sasaki, T., Nishida, M., Furuya, N., Watanabe, S., Shiotsu, S., Nishioka, N., Horinaka, M., …, & Takayama, K. (2024). AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells. Cancer Letters, 587, 216692. https://doi.org/10.1016/j.canlet.2024.216692

Vancouver

Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, et al. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells. Cancer Letters. 2024;587:216692. doi:10.1016/j.canlet.2024.216692

BibTeX
@article{Morimoto2024,
  author = {Morimoto, Kenji and Yamada, Tadaaki and Hirai, Soichi and Katayama, Yuki and Fukui, Sarina and Sawada, Ryo and Tachibana, Yusuke and Matsui, Yohei and Nakamura, Ryota and Ishida, Masaki and Kawachi, Hayato and Kunimasa, Kei and Sasaki, Takaaki and Nishida, Makoto and Furuya, Naoki and Watanabe, Satoshi and Shiotsu, Shinsuke and Nishioka, Naoya and Horinaka, Mano and Sakai, Toshiyuki and Uehara, Hisanori and Yano, Seiji and Son, Bo-Kyung and Tokuda, Shinsaku and Takayama, Koichi},
  title = {AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells},
  journal = {Cancer Letters},
  year = {2024},
  volume = {587},
  pages = {216692},
  doi = {10.1016/j.canlet.2024.216692}
}
Kostenlos starten →